Et al., 2002; Zhang et al., 2005). After the demonstration of protective actions in the cardiovascular system, relaxin was tested in human heart failure. A hemodynamic pilot study in patients with stable chronic heart failure (Dschietzig et al., 2009c) demonstrated that a 24-hour intravenous infusion of recombinant human relaxin markedly elevated cardiac index without affecting heart rate and decr